Assessement of the pharmacokinetics, tissue distribution and excretion studies of a novel antiplatelet agent S007-867, following administration to rats

S007-867 is a promising novel antiplatelet agent with better efficacy and lesser bleeding risk than existing agents. The present study investigated the absorption, tissue distribution, and excretion of S007-867 in rat model for further advancement of the molecule. A simple and robust ultra fast liqu...

Full description

Saved in:
Bibliographic Details
Published inDrug testing and analysis Vol. 8; no. 7; p. 723
Main Authors Chandasana, Hardik, Chhonker, Yashpal S, Laxman, Tulsankar Sachin, Prasad, Yarra Durga, K S, Anil Kumar, Dikshit, Dinesh K, Bhatta, Rabi S
Format Journal Article
LanguageEnglish
Published England 01.07.2016
Subjects
Administration, Oral
Animals
Chromatography, High Pressure Liquid - economics
Chromatography, High Pressure Liquid - methods
Feces - chemistry
Platelet Aggregation Inhibitors - administration & dosage
Platelet Aggregation Inhibitors - pharmacokinetics
Platelet Aggregation Inhibitors - urine
Rats
Rats, Sprague-Dawley
Tandem Mass Spectrometry - economics
Tandem Mass Spectrometry - methods
Tissue Distribution
pharmacokinetics
metabolism
excretion
rat
absorption
tissue distribution
Online AccessGet more information

Cover

More Information
Summary:S007-867 is a promising novel antiplatelet agent with better efficacy and lesser bleeding risk than existing agents. The present study investigated the absorption, tissue distribution, and excretion of S007-867 in rat model for further advancement of the molecule. A simple and robust ultra fast liquid chromatography-tandem mass spectrometry (UFLC-MS/MS) bioanalytical method was used to determine S007-867 in various matrices. Following oral administration, the compound was quickly dispersed in the various tissues and peak concentration levels were achieved within 0.5-1 h. Overall, exposure of drug, i.e., AUC in different tissues was found in the order of small intestine > liver > heart > spleen > lungs > kidney > brain. The total recoveries of the S007-867 within 96 h were 3.36% in urine and faeces. This might be due to a first-pass effect by the liver and intestine as most of the drug was eliminated in metabolite form. These findings provide a crucial information about further development of S007-867 as antithrombotic agent. Copyright © 2015 John Wiley & Sons, Ltd.
ISSN:1942-7611
DOI:10.1002/dta.1811